Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Ai-Lan Kobayashi"'
Autor:
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/40b30801152944dcaa8a5c8a21430349
Autor:
Roger H, Kobayashi, Jiří, Litzman, Isaac, Melamed, J Fernando, Mandujano, Ai Lan, Kobayashi, Bruce, Ritchie, Bob, Geng, T Prescott, Atkinson, Syed, Rehman, Sonja, Höller, Eva, Turpel-Kantor, Huub, Kreuwel, J C, Speer, Sudhir, Gupta
Publikováno v:
Clinical and Experimental Immunology. 210:91-103
A prospective study and its long-term extension examined whether weekly treatment of patients with primary immunodeficiencies (PIDs) with a 16.5% subcutaneous immunoglobulin (SCIg; cutaquig®) confers acceptable efficacy, safety, and tolerability ove
Autor:
Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan E. Walter, Ai-Lan Kobayashi, Tracy Bridges, J. Wesley Sublett, Jonathan A. Bernstein, Alan Koterba, Michael Manning, Joanna Maltese, Sonja Hoeller, Eva Turpel-Kantor, Huub Kreuwel, Roger H. Kobayashi
Publikováno v:
Journal of Clinical Immunology.
Purpose To achieve reductions in infusion time, infusion sites, and frequency, a prospective, open-label, multicenter, Phase 3 study evaluated the safety, efficacy, and tolerability of subcutaneous immunoglobulin (SCIG) 16.5% (Cutaquig®, Octapharma)
Autor:
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by
Externí odkaz:
https://doaj.org/article/4a2371e134b249bd837c68f3a41d8a8b
Autor:
Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan Walter, Ai-Lan Kobayashi, Tracy Bridges, J. Wesley Sublett, Jonathan Bernstein, Alan Koterba, Roger Kobayashi
Publikováno v:
Clinical Immunology. 250:109402
Autor:
Andrew Schechterman, Maeve O’Connor, Nazia Rashid, Holly Miranda, Isaac Melamed, Melinda Heffron, Roger H. Kobayashi, Sharon Canterberry, Ai Lan Kobayashi
Publikováno v:
Journal of Child and Adolescent Psychopharmacology
Objectives: Pediatric acute-onset neuropsychiatric syndrome (PANS) is a clinical diagnosis in children who have an acute manifestation of varied neuropsychiatric symptoms, including obsessive compulsive disorder, eating disorders, tics, anxiety, irri
Autor:
Sudhir Gupta, James DeAngelo, Isaac Melamed, Jolan Walter, Ai Lan Kobayashi, Tracy Bridges, J. Wesley Sublett, Jonathan Bernstein, Alan Koterba, Michael Manning, Joanna Maltese, Roger Kobayashi
Publikováno v:
Journal of Allergy and Clinical Immunology. 151:AB326
Autor:
Elisabeth Clodi, Jose Fernando Mandujano, Thomas Prescott Atkinson, Ai Lan Kobayashi, Eva Turpel-Kantor, Syed M. Rehman, Bob Geng, Sudhir Gupta, Roger H. Kobayashi, Isaac Melamed
Publikováno v:
Immunotherapy. 13(10)
Background: Subcutaneous human immunoglobulin (16.5%; octanorm/cutaquig®) was efficacious and well tolerated in patients with primary immunodeficiencies in a Phase III study. A subanalysis of pediatric data is presented here. Materials & methods: Ch
Autor:
Thomas Prescott Atkinson, Syed M. Rehman, J. Fernando Mandujano, Bruce Ritchie, Sudhir Gupta, Roger H. Kobayashi, Ai Lan Kobayashi, Eva Turpel-Kantor, Jiří Litzman, Bob Geng, Isaac Melamed
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 10 (2019)
Frontiers in Immunology, Vol 10 (2019)
Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by
Autor:
Hans D. Ochs, Magdalena Strach, Anna Pituch-Noworolska, Laurenz Trawnicek, Grazyna Pulka, Sudhir Gupta, Michael Borte, James N. Moy, Roger H. Kobayashi, William Smits, Ai-Lan Kobayashi, Isaac Melamed, Alan P. Knutsen
Intravenous immunoglobulin (IVIG) therapy is commonly used to treat patients with primary antibody deficiency. This prospective, open-label, non-randomised, multicentre, phase III trial investigated the pharmacokinetics of a new 10% liquid IVIG produ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01128f93f105b04f8f0b2c73daf87b41
https://ruj.uj.edu.pl/xmlui/handle/item/116981
https://ruj.uj.edu.pl/xmlui/handle/item/116981